Tissue Plasminogen Activator Market Regional Analysis

Tissue Plasminogen Activator Market, By Drug Type (Alteplase, Reteplase, Tenecteplase), By Application (Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI2469

Pages :141

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Global Tissue Plasminogen Activator Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global tissue plasminogen activator market over the forecast period. North America is estimated to hold 40.1 % of the market share in 2023. The market is expected to witness significant growth in the near future due to rising product approvals by regulatory authorities in U.S. For instance, in June 2021, the U.S. Food and Drug Administration (FDA) had authorized or approved Ryplazim (plasminogen, human-tvmh) a drug developed by ProMetic Biotherapeutics Inc., a biopharmaceutical company for the treatment of individuals with plasminogen deficiency type 1, commonly known as hypoplasminogenemia, a disease that can impede normal tissue and organ function and can lead to blindness.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa